Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06963216 · ClinicalTrials.gov registry record · Phase 3
A Study Investigating Coagadex in the Treatment AFXD Associated With AL Amyloidosis
A Phase 3 study of Acquired Factor X Deficiency, sponsored by Kedrion S.p.A..
- Recruiting
- Registry status
- Phase 3
- Development phase
- 15
- Enrollment target
- 3
- Study locations
NCT06963216: Recruiting Phase 3 study of Acquired Factor X Deficiency, sponsored by Kedrion S.p.A..
NCT06963216 is a Phase 3 study of Acquired Factor X Deficiency that is actively recruiting participants, run by Kedrion S.p.A.. The registered enrollment target is 15 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (98% lower). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06963216, a Phase 3 study of Acquired Factor X Deficiency, is actively recruiting participants, sponsored by Kedrion S.p.A..
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 15 participants
- Enrollment target
- 3
- Study locations
Study Summary
The purpose of this study is to evaluate the efficacy and safety of Coagadex in treating active bleeds and to manage peri-operative bleeding in participants with acquired factor X deficiency associated with AL amyloidosis.
Conditions Studied
Interventions
- BIOLOGICAL Coagadex(R)
Study Locations (3)
Arizona
- Mayo Clinic Arizona - Phoenix
Minnesota
- Mayo Clinic Rochester - Rochester
London
- Cancer Clinical Trials Unit - London
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2026-02 |
| Est. Completion | 2027-09 |
| Phase | Phase 3 |
What NCT06963216 shows while recruiting
NCT06963216 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 15 participants, a relatively small participant target, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (98% lower).
The record links to 1 condition, with Acquired Factor X Deficiency appearing as the primary indexed condition, and to 1 intervention - of which Coagadex(R) is the first listed.
NCT06963216 reports a single indexed study location in Arizona, Minnesota, London.
Frequently Asked Questions
What is clinical trial NCT06963216 about?
NCT06963216 is a clinical study titled "A Study Investigating Coagadex in the Treatment AFXD Associated With AL Amyloidosis". The purpose of this study is to evaluate the efficacy and safety of Coagadex in treating active bleeds and to manage peri-operative bleeding in participants with acquired factor X deficiency associated with AL amyloidosis.
What is the current status of trial NCT06963216?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 15 participants. The study started on 2026-02. Estimated completion is 2027-09.
What conditions does trial NCT06963216 study?
This clinical trial studies the following conditions: Acquired Factor X Deficiency.
What interventions are being tested in trial NCT06963216?
The interventions under investigation include: Coagadex(R) (BIOLOGICAL).
Who is sponsoring clinical trial NCT06963216?
This trial is sponsored by Kedrion S.p.A., which has 8 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06963216 being conducted?
This trial has 3 study locations across Arizona, Minnesota, London. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06963216's enrollment target sits among peer trials
15 1978th of 2000 higher than 18 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01889381 · 15 participants · Phase 2
Human Craniomaxillofacial Allotransplantation
- NCT02530073 · 15 participants · NA
Trial of Fetoscopic Endoluminal Tracheal Occlusion (FETO) for CDH
- NCT02535936 · 15 participants · NA
Cortical Plasticity in Spastic Diplegia After Selective Dorsal Rhizotomy
- NCT02918474 · 15 participants · NA
Decision Making Tool in Supporting Decision Making in Contralateral Prophylactic Mastectomy in Patients With Newly Diagnosed Breast Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia